Lysoclear is an innovative brand that specializes in developing enzyme therapies for eye diseases. As a pre-clinical company under the portfolio of Ichor Therapeutics, Lysoclear is dedicated to finding effective treatments for atrophic dry age-related macular degeneration and Stargardt's macular degeneration. The science behind Lysoclear's products focuses on the gradual loss of retinal pigmented epithelial (RPE) cells in the macula, the part of the eye responsible for central vision.

These diseases are associated with the accumulation of toxic vitamin A aggregates, which inhibit the function of lysosomal enzymes. Lysoclear's recombinant enzyme product, currently under development, selectively localizes to the lysosomes of RPE cells, destroying the toxic aggregates. Operational in a similar manner to existing therapies for lysosomal storage diseases, Lysoclear introduces a new enzyme that upgrades RPE cells, enabling them to degrade harmful substances like A2E and other lipofuscin components.

If you're interested in learning more about Lysoclear and their groundbreaking research, reach out to them through their website